These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

702 related articles for article (PubMed ID: 29882203)

  • 21. IL-1β, IL-17A, CRP and biologics history might serve as potential markers for clinical response to etanercept in rheumatoid arthritis patients.
    Zhang B; Jiang W
    Inflammopharmacology; 2019 Dec; 27(6):1123-1130. PubMed ID: 31463666
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Etanercept is effective as monotherapy or in combination with methotrexate in rheumatoid arthritis: subanalysis of an observational study.
    Gaubitz M; Göttl KH; Behmer O; Lippe R; Meng T; Löschmann PA
    Clin Rheumatol; 2017 Sep; 36(9):1989-1996. PubMed ID: 28756532
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy.
    van der Heijde D; Burmester G; Melo-Gomes J; Codreanu C; Mola EM; Pedersen R; Freundlich B; Chang DJ;
    Ann Rheum Dis; 2008 Feb; 67(2):182-8. PubMed ID: 17728331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Zymographic analysis using gelatin-coated film of the effect of etanercept on the extracellular matrix-degrading activity in synovial fluids of rheumatoid arthritis patients.
    Kamataki A; Ishida M; Komagamine M; Yoshida M; Ando T; Sawai T
    Int J Rheum Dis; 2016 Apr; 19(4):385-91. PubMed ID: 24618272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study.
    van Riel PL; Taggart AJ; Sany J; Gaubitz M; Nab HW; Pedersen R; Freundlich B; MacPeek D;
    Ann Rheum Dis; 2006 Nov; 65(11):1478-83. PubMed ID: 16464988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis.
    Emery P; Vencovský J; Sylwestrzak A; Leszczynski P; Porawska W; Baranauskaite A; Tseluyko V; Zhdan VM; Stasiuk B; Milasiene R; Barrera Rodriguez AA; Cheong SY; Ghil J
    Rheumatology (Oxford); 2017 Dec; 56(12):2093-2101. PubMed ID: 28968793
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of response to etanercept-methotrexate treatment: a post hoc logistic regression analysis of a randomized, open-label study in Latin American patients with rheumatoid arthritis.
    de la Vega M; Guerra Bautista G; Xavier RM; Pacheco-Tena C; Solano G; Pedersen RD; Szumski AE; Borlenghi C; Santana K; Vlahos B
    Adv Rheumatol; 2021 Sep; 61(1):56. PubMed ID: 34496979
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis.
    Fleischmann R; Koenig AS; Szumski A; Nab HW; Marshall L; Bananis E
    Rheumatology (Oxford); 2014 Nov; 53(11):1984-93. PubMed ID: 24907147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis.
    Tanaka Y; Smolen JS; Jones H; Szumski A; Marshall L; Emery P
    Arthritis Res Ther; 2019 Jul; 21(1):164. PubMed ID: 31277720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis.
    Weinblatt ME; McInnes IB; Kremer JM; Miranda P; Vencovsky J; Guo X; White WI; Ryan PC; Godwood A; Albulescu M; Close D; Burmester GR
    Arthritis Rheumatol; 2018 Jan; 70(1):49-59. PubMed ID: 28941039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum Calprotectin Versus Acute-Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors.
    Inciarte-Mundo J; Victoria Hernández M; Ruiz-Esquide V; Raquel Cabrera-Villalba S; Ramirez J; Cuervo A; Pascal M; Yagüe J; Cañete JD; Sanmarti R
    Arthritis Care Res (Hoboken); 2016 Jul; 68(7):899-906. PubMed ID: 26841119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA.
    Keystone E; Freundlich B; Schiff M; Li J; Hooper M
    J Rheumatol; 2009 Mar; 36(3):522-31. PubMed ID: 19228659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of response with etanercept-methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study.
    Pavelka K; Szekanecz Z; Damjanov N; Majdan M; Nasonov E; Mazurov V; Fabo T; Bananis E; Jones H; Szumski A; Tang B; Kotak S; Koenig AS; Vasilescu R
    Clin Rheumatol; 2013 Sep; 32(9):1275-81. PubMed ID: 23666316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the efficacy and safety of etanercept 50 mg once weekly in Japanese patients with rheumatoid arthritis and comparison with 25 mg etanercept twice weekly.
    Mochizuki T; Momohara S; Yano K; Shirahata T; Ikari K
    Mod Rheumatol; 2013 Sep; 23(5):994-1000. PubMed ID: 23138447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept.
    Buch MH; Seto Y; Bingham SJ; Bejarano V; Bryer D; White J; Emery P
    Arthritis Rheum; 2005 Jan; 52(1):42-8. PubMed ID: 15641046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study.
    Blanco FJ; Möricke R; Dokoupilova E; Codding C; Neal J; Andersson M; Rohrer S; Richards H
    Arthritis Rheumatol; 2017 Jun; 69(6):1144-1153. PubMed ID: 28217871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etanercept in patients with moderately active rheumatoid arthritis despite DMARD therapy.
    Hobbs K; Deodhar A; Wang B; Bitman B; Nussbaum J; Chung J; Collier DH
    Springerplus; 2015; 4():113. PubMed ID: 25793152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies.
    Schiff MH; Yu EB; Weinblatt ME; Moreland LW; Genovese MC; White B; Singh A; Chon Y; Woolley JM
    Drugs Aging; 2006; 23(2):167-78. PubMed ID: 16536638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential response of serum amyloid A to different therapies in early rheumatoid arthritis and its potential value as a disease activity biomarker.
    Hwang YG; Balasubramani GK; Metes ID; Levesque MC; Bridges SL; Moreland LW
    Arthritis Res Ther; 2016 May; 18(1):108. PubMed ID: 27188329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adsorptive granulocyte/monocyte apheresis for the treatment of refractory rheumatoid arthritis: an open pilot multicentre trial.
    Sanmartí R; Marsal S; Valverde J; Casado E; Lafuente R; Kashiwagi N; Rodriguez-Cros JR; Erra A; Reina D; Gratacós J
    Rheumatology (Oxford); 2005 Sep; 44(9):1140-4. PubMed ID: 15927997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.